Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development
Hui Yao, Sophie F. Hill, Jennifer M. Skidmore, Ethan D. Sperry, Donald L. Swiderski, Gilson J. Sanchez, Cynthia F. Bartels, Yehoash Raphael, Peter C. Scacheri, Shigeki Iwase, Donna M. Martin
Hui Yao, Sophie F. Hill, Jennifer M. Skidmore, Ethan D. Sperry, Donald L. Swiderski, Gilson J. Sanchez, Cynthia F. Bartels, Yehoash Raphael, Peter C. Scacheri, Shigeki Iwase, Donna M. Martin
View: Text | PDF
Research Article Development Neuroscience

CHD7 represses the retinoic acid synthesis enzyme ALDH1A3 during inner ear development

  • Text
  • PDF
Abstract

CHD7, an ATP-dependent chromatin remodeler, is disrupted in CHARGE syndrome, an autosomal dominant disorder characterized by variably penetrant abnormalities in craniofacial, cardiac, and nervous system tissues. The inner ear is uniquely sensitive to CHD7 levels and is the most commonly affected organ in individuals with CHARGE. Interestingly, upregulation or downregulation of retinoic acid (RA) signaling during embryogenesis also leads to developmental defects similar to those in CHARGE syndrome, suggesting that CHD7 and RA may have common target genes or signaling pathways. Here, we tested three separate potential mechanisms for CHD7 and RA interaction: (a) direct binding of CHD7 with RA receptors, (b) regulation of CHD7 levels by RA, and (c) CHD7 binding and regulation of RA-related genes. We show that CHD7 directly regulates expression of Aldh1a3, the gene encoding the RA synthetic enzyme ALDH1A3 and that loss of Aldh1a3 partially rescues Chd7 mutant mouse inner ear defects. Together, these studies indicate that ALDH1A3 acts with CHD7 in a common genetic pathway to regulate inner ear development, providing insights into how CHD7 and RA regulate gene expression and morphogenesis in the developing embryo.

Authors

Hui Yao, Sophie F. Hill, Jennifer M. Skidmore, Ethan D. Sperry, Donald L. Swiderski, Gilson J. Sanchez, Cynthia F. Bartels, Yehoash Raphael, Peter C. Scacheri, Shigeki Iwase, Donna M. Martin

×

Figure 5

Retinoic acid does not affect CHD7 levels in SH-SY5Y cells.

Options: View larger image (or click on image) Download as PowerPoint
Retinoic acid does not affect CHD7 levels in SH-SY5Y cells.
Western blot...
Western blotting of CHD7 and CHD5 levels in various cell types. HDAC2 is used a loading control. Each experiment was performed at least 2 times. (A) Treatment with 10 μM all-trans retinoic acid (ATRA) increased CHD5 levels and had no effect on CHD7 levels over 12 days. (B) Treatment with 1, 5, or 10 μM ATRA for 7 or 12 days mildly induced CHD5 levels and had no effect on CHD7. (C) Treatment with 10 μM 13-cis retinoic acid (13-cis-RA) for 6 days increased CHD5 levels but had no effect on CHD7 levels relative to treatment with DMSO only. (D) Treatment with 1, 5, or 10 μM 13-cis-RA for 7 or 12 days induced CHD5 levels and had no effect on CHD7 levels. (E) Treatment with ATRA (1, 5, or 10 μM) or citral (1, 5, or 10 μM) for 3 days had no effect on CHD7 levels. (F) Treatment with 10 μM DEAB for 3 days had no major effect on CHD7 levels. This experiment was repeated twice. (G) CHD7 levels were lower in neural progenitor cells derived from forebrains of E12.5 Chd7Gt/+ embryos compared with Chd7+/+ embryos. (H) Treatment with 10 μM ATRA or 10 μM citral had no effect on CHD7 levels relative to DMSO vehicle control in neural progenitors derived from forebrains of E12.5 Chd7+/+ or Chd7Gt/+ mice.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts